|Day Low/High||152.09 / 154.10|
|52 Wk Low/High||119.38 / 190.35|
LH's $5.7B Covance takeover could be just what the doctor ordered.
Most of the Lab Corp. of America's key metrics approximately tripled from 2005 through 2015.
This entry is in response to a question posed by FreakGuy666. It all hinges on what you mean by "under the radar?" I take it to mean those diamonds in the rough that lack Wall Street research coverage or fall below the $5 price threshold. One that f...
We saw this coming, but there's more to the recent turmoil than China.
Conditions still appear grim, but these picks should be able to weather the storm.
Selling covered calls and naked puts can reduce risk. (Updated)
Try this options play for the sometimes volatile Bio-Reference Laboratories.
Quest Diagnostics -- and others in this beaten-down sector -- are excellent trading vehicles.
Bio-Reference Labs CEO Dr. Marc Grodman says the Supreme Court ruling against human gene patents means big things for the testing industry.
The fear of 'dead money' has brought Quest back to an extremely low-risk entry point.
This is one of the few stocks still trading at a bargain valuation.